Notfälle in der Hämatologie und Onkologie

Schlüsselwörter

Tumorhyperkalzämie - Hyperviskositätssyndrom - Tumorlysesyndrom - Vena-cava-superior-Syndrom - maligner Perikarderguss

Keywords

tumor associated hypercalcemia - hyperviscosity syndrome - tumor lysis syndrome - Vena-cava-superior syndrome - malignant pericardial effusion

Literatur

• 1 Annemans L, Moeremans K, Lamotte M. et al . Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin’s lymphoma in four European countries.  Leuk Lymphoma. 2003;  44 77-83
• 2 Armstrong B A, Perez C A, Simpson J R, Hederman M A. Role of irradiation in the management of superior vena cava syndrome.  Int J Radiat Oncol Biol Phys. 1987;  13 531-539
• 3 Blum W, Porcu P. Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome.  Semin Thromb Hemost. 2007;  33 350-354
• 4 Body J J. Hypercalcemia of malignancy.  Semin Nephrol. 2004;  24 48-54
• 5 Böhme A, Ruhnke M, Karthaus M. et al . Therapie von Pilzinfektionen in der Hämatologie und Onkologie. Leitlinien der Arbeitsgemeinschaft Infektionen in der Hämatologie und Onkologie (AGIHO) der Deutschen Gesellschaft für Hämatologie und Onkologie (DGHO).   Dtsch Med Wochenschr. 2001;  126 1440-1447
• 6 Buchheidt D, Böhme A, Cornely O. et al . Dokumentierte Infektionen bei Neutropenie - Empfehlungen zu Diagnostik und Therapie. Arbeitsgemeinschaft Infektionen in der Hämatologie und Onkologie - Fachgruppe der Deutschen Gesellschaft für Hämatologie und Onkologie.  Dtsch Med Wochenschr. 2001;  126 1085-1090
• 7 Cairo M S. Prevention and treatment of hyperuricemia in hematological malignancies.  Clin Lymphoma. 2002;  3 (Suppl 1) S26-S31
• 8 Cairo M S, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification.  Br J Haematol. 2004;  127 3-11
• 9 Clines G A, Guise T A. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone.  Endocr Relat Cancer. 2005;  12 549-583
• 10 Coiffier B, Altman A, Pui C H, Younes A, Cairo M S. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.  J Clin Oncol. 2008;  26 2767-2778
• 11 Dequanter D, Lothaire P, Berghmans T, Sculier J P. Severe pericardial effusion in patients with concurrent malignancy: a retrospective analysis of prognostic factors influencing survival.  Ann Surg Oncol. 2008;  15 3268-3271
• 12 Dimopoulos M A, Kyle R A, Anagnostopoulos A, Treon S P. Diagnosis and management of Waldenstrom’s macroglobulinemia.  J Clin Oncol. 2005;  23 1564-1577
• 13 Halfdanarson T R, Hogan W J, Moynihan T J. Oncologic emergencies: diagnosis and treatment.  Mayo Clin Proc. 2006;  81 835-848
• 14 Higdon M L, Higdon J A. Treatment of oncologic emergencies.  Am Fam Physician. 2006;  74 1873-1880
• 15 Karam N, Patel P, deFilippi C. Diagnosis and management of chronic pericardial effusions.  Am J Med Sci. 2001;  322 79-87
• 16 Karatolios K, Maisch B. Die Perikardbiopsie.  Dtsch Med Wochenschr. 2007;  132 1707-1710
• 17 Kremer R, Shustik C, Tabak T, Papavasiliou V, Goltzman D. Parathyroid-hormone-related peptide in hematologic malignancies.  Am J Med. 1996;  100 406-411
• 18 Kunitoh H, Tamura T, Shibata T. et al . A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811).  Br J Cancer. 2009;  100 464-469
• 19 Mehta J, Singhal S. Hyperviscosity syndrome in plasma cell dyscrasias.  Semin Thromb Hemost. 2003;  29 467-471
• 20 Ostler P J, Clarke D P, Watkinson A F, Gaze M N. Superior vena cava obstruction: a modern management strategy.  Clin Oncol (R Coll Radiol ). 1997;  9 83-89
• 21 Parish J M, Marschke Jr R F, Dines D E, Lee R E. Etiologic considerations in superior vena cava syndrome.  Mayo Clin Proc. 1981;  56 407-413
• 22 Roodman G D. Pathogenesis of myeloma bone disease.  Leukemia. 2009;  23 435-441
• 23 Stewart A F. Clinical practice. Hypercalcemia associated with cancer.  N Engl J Med. 2005;  352 373-379
• 24 Thomas L, Kwok Y, Edelman M J. Management of paraneoplastic syndromes in lung cancer.  Curr Treat Options Oncol. 2004;  5 51-62
• 25 Uaje C, Kahsen K, Parish L. Oncology emergencies.  Crit Care Nurs Q. 1996;  18 26-34
• 26 Urruticoechea A, Mesia R, Dominguez J. et al . Treatment of malignant superior vena cava syndrome by endovascular stent insertion. Experience on 52 patients with lung cancer.  Lung Cancer. 2004;  43 209-214
• 27 Van Poznak C. Hypercalcemia of malignancy remains a clinically relevant problem.  Cancer J. 2006;  12 21-23
• 28 Wilkes J D, Fidias P, Vaickus L, Perez R P. Malignancy-related pericardial effusion. 127 cases from the Roswell Park Cancer Institute.  Cancer. 1995;  76 1377-1387
• 29 Wilson L D, Detterbeck F C, Yahalom J. Clinical practice. Superior vena cava syndrome with malignant causes.  N Engl J Med. 2007;  356 1862-1869
• 30 Zarkovic M, Kwaan H C. Correction of hyperviscosity by apheresis.  Semin Thromb Hemost. 2003;  29 535-542